The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions

[1]  D. Krueger,et al.  Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis , 2015, Annals of neurology.

[2]  P. J. Vries,et al.  Neurological and neuropsychiatric aspects of tuberous sclerosis complex , 2015, The Lancet Neurology.

[3]  O. Witt,et al.  Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. , 2014, The Lancet. Oncology.

[4]  P. Bruzzi,et al.  TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex , 2014, Orphanet Journal of Rare Diseases.

[5]  K. Kotulska,et al.  EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients - a prospective study of 5 patients. , 2014, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[6]  B. Kaplan,et al.  Strategies for the management of adverse events associated with mTOR inhibitors. , 2014, Transplantation reviews.

[7]  B. Korf,et al.  The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  M. Roszkowski,et al.  Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. , 2014, Pediatric neurology.

[9]  D. Demuth,et al.  318 Real-world assessment of renal involvement in tuberous sclerosis complex (TSC) patients in the United Kingdom (UK) , 2014 .

[10]  C. Michel,et al.  The Role of Functional Neuroimaging in Pre-Surgical Epilepsy Evaluation , 2014, Front. Neurol..

[11]  M. Piccart,et al.  Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Weiner,et al.  Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. , 2013, Pediatric neurology.

[13]  A. Wilfong,et al.  Treating Epilepsy in Tuberous Sclerosis with Everolimus: Getting Closer , 2014, Epilepsy currents.

[14]  D. Krueger,et al.  Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.

[15]  Hope Northrup,et al.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. , 2013, Pediatric neurology.

[16]  F. Garaci,et al.  Is mTOR inhibition a systemic treatment for tuberous sclerosis? , 2013, Italian Journal of Pediatrics.

[17]  K. Kotulska,et al.  Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  Jian-Guo Zhang,et al.  Predictors of seizure freedom after surgical management of tuberous sclerosis complex: A systematic review and meta-analysis , 2013, Epilepsy Research.

[19]  S. Jóźwiak,et al.  Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[20]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[21]  N. Rensing,et al.  Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex , 2013, PloS one.

[22]  D. Krueger,et al.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma , 2013, Neurology.

[23]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[24]  P. Curatolo,et al.  Send Orders of Reprints at Reprints@benthamscience.org Mtor Inhibitors in Tuberous Sclerosis Complex , 2022 .

[25]  S. Jóźwiak,et al.  Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[26]  A. von Eckardstein,et al.  Low-Dose Oral Sirolimus and the Risk of Menstrual-Cycle Disturbances and Ovarian Cysts: Analysis of the Randomized Controlled SUISSE ADPKD Trial , 2012, PloS one.

[27]  E. Thiele,et al.  Low glycemic index treatment for epilepsy in tuberous sclerosis complex , 2012, Epilepsy Research.

[28]  M. Curran Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. , 2012, Paediatric drugs.

[29]  P. Curatolo,et al.  Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis , 2011, Epilepsy & Behavior.

[30]  J. Manola,et al.  Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease , 2011, PloS one.

[31]  K. Kotulska,et al.  Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[32]  D. Franz Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis , 2011, Expert review of anticancer therapy.

[33]  J. Swann,et al.  Treatment of Infantile Spasms , 2011, Journal of child neurology.

[34]  K. Pointon,et al.  Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial , 2011, Clinical Cancer Research.

[35]  Kelvin A. Yamada,et al.  The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway , 2011, Epilepsia.

[36]  P. Curatolo,et al.  The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective , 2011, Child's Nervous System.

[37]  A. Zwinderman,et al.  Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. , 2010, Kidney international.

[38]  J. Bissler,et al.  Tuberous Sclerosis Complex Renal Disease , 2010, Nephron Experimental Nephrology.

[39]  P. Curatolo,et al.  Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. , 2010, Pediatric neurology.

[40]  P. Curatolo,et al.  Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[41]  O. Devinsky,et al.  Refractory epilepsy in tuberous sclerosis: Vagus nerve stimulation with or without subsequent resective surgery , 2009, Epilepsy & Behavior.

[42]  A. Cooney,et al.  Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles , 2009, Human molecular genetics.

[43]  L. James Willmore,et al.  Vigabatrin: 2008 Update , 2009, Epilepsia.

[44]  S. Jóźwiak,et al.  Tuberous sclerosis , 2008, The Lancet.

[45]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[46]  E. Kossoff,et al.  Tuberous Sclerosis Complex and the Ketogenic Diet , 2005, Epilepsia.

[47]  S. Segal,et al.  Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  J. Osborne,et al.  The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[49]  K. Kotulska,et al.  Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[50]  J. Stockman,et al.  Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .

[51]  A. Ouweland,et al.  Missense mutations to the TSC1 gene cause tuberous sclerosis complex , 2009, European Journal of Human Genetics.

[52]  H. Zincke,et al.  Update on tuberous sclerosis complex. , 2001, Contributions to nephrology.